FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to oncology, and can be used to determine the area of skin edema in patients with locally advanced breast cancer. A mammogram (MMG) is performed. The surface area of the mammary gland is calculated using the formula S=2πrh, where S is the surface area of the mammary gland, r is the radius, and h is the height. The area of local edema is calculated by the formula Sl=((a1+a2)+(b1+b2))π/2, where S1 is the area of local edema, a1 and a2 are the sides of the triangle in the frontal projection, b1 and b2 are the sides of the triangle in sagittal projection on MMG images. At the same time, the base of the triangle in the frontal and sagittal projections of the MMG is the segment that delimits the local edema from the mammary gland. The area of breast skin edema S1 (%) is determined by the formula Sl(%)=(Sl/S)100%.
EFFECT: method allows to evaluate the dynamics of the tumor process against the background of neoadjuvant drug treatment by determining the area of the edema.
1 cl, 6 dwg, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF DIAGNOSING REGRESSION OF BREAST CANCER AFTER NEOADJUVANT DRUG THERAPY | 2022 |
|
RU2806299C1 |
METHOD FOR DIFFERENTIATED TREATMENT OF PATIENTS WITH LOCALIZED BREAST CANCER | 2017 |
|
RU2637859C1 |
METHOD OF FINE-NEEDLE ASPIRATION BIOPSY OF PARASTERNAL LYMPH NODES IN PATIENTS WITH BREAST CANCER | 2019 |
|
RU2701352C1 |
METHOD OF TREATING PATIENTS WITH BRCA-ASSOCIATED TRIPLE-NEGATIVE LOCALLY ADVANCED BREAST CANCER | 2023 |
|
RU2814578C1 |
METHOD FOR EVALUATING OVARIAN FUNCTION IN BREAST CANCER PATIENTS OF REPRODUCTIVE AGE WHO UNDERWENT NEOADJUVANT CHEMOTHERAPY | 2012 |
|
RU2482490C1 |
METHOD OF PERFORMING ORGAN-CONSERVING SURGERY BY VACUUM-ASSISTED BIOPSY OF BREAST TUMOR BED AFTER NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH HER2-DEPENDENT OR TRIPLE-NEGATIVE BREAST CANCER SUBTYPE | 2023 |
|
RU2810795C1 |
METHOD FOR DETERMINING THE PROGNOSIS OF THE EFFECTIVENESS OF BREAST CANCER THERAPY | 2021 |
|
RU2757590C1 |
METHOD OF COMBINED TREATMENT OF PATIENTS WITH PRIMARILY OPERABLE AND LOCALLY ADVANCED INOPERABLE BREAST CANCER | 2017 |
|
RU2664597C1 |
METHOD FOR PREDICTION OF FULL REGRESSION PROBABILITY DURING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH THREE-TIMES NEGATIVE MOLECULAR-GENETIC SUBTYPE OF BREAST CANCER | 2016 |
|
RU2623118C1 |
METHOD FOR ORGAN-PRESERVING TREATMENT OF OPERABLE RECTAL CANCER | 2020 |
|
RU2740361C1 |
Authors
Dates
2022-10-28—Published
2022-02-10—Filed